Results 231 to 240 of about 42,056 (305)

FACS-based genome-wide CRISPR screening platform identifies modulators of CD47. [PDF]

Front Immunol
Yin L, He W, Wang Y, Zhang H, Huang M, Yan Y, Li S, Feng X, Saenz F, Zhang J, Zhu D, Yang C, Ma T, Fu J, Chen J.   +14 more
europepmc   +1 more source

If Plan A Does Not Work: The CD47 Ectodomain as a Target for Immune Tolerance. [PDF]

Cells
Montero E, Isenberg JS.
europepmc   +1 more source

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. [PDF]

Nat Commun
Ha J, Wang Y, Ma Y, Wu A, Dong S, Jeong SD, Edwards JL, Chang M, Chang YT, Wang X, Dufilho M, Najarro Torres M, McCabe S, Deng W, Grippin AJ, Weinberg JS, Raza SM, DeMonte F, McCutcheon IE, Prabhu S, Ferguson SD, Ene CI, Akdemir K, Basu S, Jindal S, Schrank BR, Hu J, Goswami S, Puduvalli VK, Lang FF, Huntoon K, Sharma P, Kim BYS, Jiang W.   +33 more
europepmc   +1 more source

Evaluating the effect of CD47 expression levels and clinicopathologic features on survival function in resected uterine carcinosarcoma: the Western Turkey example. [PDF]

BMC Cancer
Keser M, Semiz HS, Cakir I, Muharremoglu ZD, Unal OU, Akagunduz B, Pala EE.   +6 more
europepmc   +1 more source

An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma. [PDF]

iScience
Pan L, Zhu X, Zhang J, Zhong Q, Wu H, Sun W, Xia Y, Wang S, Tong X.   +8 more
europepmc   +1 more source

Metformin suppresses PPARδ-driven CD47 transcription to enhance macrophage phagocytosis in lung cancer. [PDF]

J Biol Chem
Cui Q, Wang H, Yu H, Li Y, Wang Y, Shi J, Hou Y.   +6 more
europepmc   +1 more source

The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma. [PDF]

Immunotargets Ther
Matar S, Skah S, Moltu LEB, Åmellem Ø, Hagland HR, Hestdal K, Pettersen RD, Richartz N.   +7 more
europepmc   +1 more source

Advancements in nanomedicine for the therapeutic regulation of efferocytosis: opportunities and challenges. [PDF]

Theranostics
Lin Z, Zhou X, Liu S, Wan M, Liu J.
europepmc   +1 more source

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. [PDF]

ESMO Gastrointest Oncol
Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR.   +19 more
europepmc   +1 more source